Extended Duration of Adjuvant Temozolomide in Glioblastoma Multiforme - A Review of Trials

被引：0
|
作者：
Pruthi, Deep Shankar [1 ]
Nagpal, Puneet [1 ]
Pandey, Manish [1 ]
机构：
[1] Act Canc Hosp, Dept Radiat Oncol, A-4, New Delhi, India
来源：
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY | 2021年 / 5卷 / 03期
关键词：
Adjuvant; Glioblastoma Multiforme; Extended duration; Temozolomide; NEWLY-DIAGNOSED GLIOBLASTOMA; RANDOMIZED PHASE-III; PROLONGED TEMOZOLOMIDE; OPEN-LABEL; RADIOTHERAPY; CONCOMITANT; SURVIVAL; THERAPY;
D O I：
10.14744/ejmo.2021.20733
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) chemotherapy then adjuvant TMZ is the current standard treatment for glioblastoma multiforme (GBM). There is a lot of controversy regarding the duration of adjuvant TMZ. The standard guidelines recommend 6 months of adjuvant treatment, however in clinical practice in a lot of centers around the world, TMZ therapy is continued beyond 6 months duration. In this review article we will discuss both favorable and unfavorable trials regarding extended TMZ therapy and try to analyze in whom extended TMZ therapy is beneficial and whether or not it should be offered.
引用
收藏
页码：217 / 221
页数：5
相关论文
共 50 条
  • [1] Extended duration temozolomide in patients with glioblastoma multiforme.
    Pitz, M. W.
    Lipson, M. E.
    Hoseini, B.
    Guilbert, K.
    Lister, A.
    Mihalcioiu, C. L.
    Eisenstat, D. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
    Urgoiti, Gloria B. Roldan
    Singh, Amitabh D.
    Easaw, Jacob C.
    JOURNAL OF NEURO-ONCOLOGY, 2012, 108 (01) : 173 - 177
  • [3] Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
    Gloria B. Roldán Urgoiti
    Amitabh D. Singh
    Jacob C. Easaw
    Journal of Neuro-Oncology, 2012, 108 : 173 - 177
  • [4] The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
    Alimohammadi, Ehsan
    Bagheri, Seyed Reza
    Taheri, Shahram
    Dayani, Maliheh
    Abdi, Alireza
    ONCOLOGY REVIEWS, 2020, 14 (01) : 17 - 22
  • [5] Toxicity of concurrent and adjuvant temozolomide in patients with glioblastoma multiforme (GBM).
    Mcmahon, David
    Hussein, Awab
    Mangleburg, Hunter
    Nichianain, Aine
    Fitzpatrick, Orla
    McLaughlin, Ronan Andrew
    Conroy, Michael R.
    Marks, Sam Jonathan
    Naidoo, Jarushka
    Grogan, William
    Murphy, Adrian Gerard
    Breathnach, Oscar S.
    Hennessy, Bryan T.
    Morris, Patrick G.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [6] Efficacy and safety of extended adjuvant temozolomide compared to standard adjuvant temozolomide in glioblastoma: Updated systematic review and meta-analysis
    Gupta, Tejpal
    Talukdar, Riddhijyoti
    Kannan, Sadhana
    Dasgupta, Archya
    Chatterjee, Abhishek
    Patil, Vijay
    NEURO-ONCOLOGY PRACTICE, 2022, 9 (05) : 354 - 363
  • [7] Patterns of recurrence and outcomes of glioblastoma multiforme treated with chemoradiation and adjuvant temozolomide
    Faustino, Alexandre Ciuffi
    Viani, Gustavo Arruda
    Hamamura, Ana Carolina
    CLINICS, 2020, 75 : 1 - 6
  • [8] RADIOTHERAPY WITH CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME PATIENTS: A PROSPECTIVE STUDY
    Sarihan, S.
    Yildirim, S.
    Ozturk, H.
    Evrensel, T.
    Kocaeli, H.
    Tolunay, S.
    RADIOTHERAPY AND ONCOLOGY, 2008, 88 : S216 - S216
  • [9] NEOADJUVANT (PRE RADIOTHERAPY) TEMOZOLOMIDE FOLLOWED BY RADIATION THERAPY WITH CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN GLIOBLASTOMA MULTIFORME
    Prajapati, Chinmaykumar
    Mehta, Maitrik
    Kunikullaya, U. Suryanarayan
    NEURO-ONCOLOGY, 2021, 23 : 45 - 45
  • [10] Optimal duration of adjuvant temozolomide in glioblastoma: An unsolved and unsolvable problem
    Balana, Carmen
    NEURO-ONCOLOGY PRACTICE, 2022, 9 (05) : 349 - 350
12345